Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCKDK | O14874 | 2/20 | 0.77 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | TLR3 | O15455 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1255148 | 0.87 | BCKDK (0.58) | BCKDKRAB9ASENP1KDM4ESMN1; SMN2 | |
| SCHEMBL594468 | 0.87 | BCKDK (1.00) | BCKDKRAB9ASENP1KDM4ESMN1; SMN2 | |
| SCHEMBL2610278 | 0.85 | BCKDK (0.74) | BCKDKRAB9ASENP1KDM4ESMN1; SMN2 | |
| SCHEMBL2723054 | 0.83 | BCKDK (0.75) | BCKDKRAB9AKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL693146 | 0.81 | BCKDK (0.68) | BCKDKRAB9ASENP1KDM4ESMN1; SMN2 | |
| SCHEMBL8278999 | 0.81 | BCKDK (0.68) | BCKDKRAB9ASENP1KDM4ESMN1; SMN2 | |
| SCHEMBL12726993 | 0.81 | BCKDK (0.68) | BCKDKRAB9ASENP1KDM4ESMN1; SMN2 | |
| SCHEMBL13659611 | 0.81 | BCKDK (0.68) | BCKDKRAB9ASENP1KDM4ESMN1; SMN2 | |
| SCHEMBL31053391 | 0.80 | BCKDK (0.71) | BCKDKRAB9ASENP1KDM4ESMN1; SMN2 | |
| SCHEMBL9720128 | 0.80 | BCKDK (0.67) | BCKDKRAB9ASENP1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070921-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | UNIV KYOTO (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4582430-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | Kyoto University (JP) | 2025-07-09 | — | — | EP | disclosed |
| CN-115710248-B | Novel selective estrogen receptor down-regulator compound, preparation method and application | 南京中医药大学 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024048697-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | 国立大学法人京都大学 | 2024-03-07 | — | — | WO | disclosed |
| CN-115710248-A | Novel selective estrogen receptor down-regulator compounds, methods of preparation and uses | 南京中医药大学 | 2023-02-24 | — | — | CN | disclosed |
| CN-109928967-B | Cyclized berberine derivative and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2020-09-04 | — | — | CN | disclosed |
| US-9493489-B2 | Boron-containing small molecules as anti-protozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9409880-B2 | Modulators of TLR3/dsRNA complex and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-08-09 | — | — | US | disclosed |
| US-9382237-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9346792-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-8399454-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-19 | — | — | US | disclosed |
| WO-2012099785-A2 | MODULATORS OF TLR3/DSRNA COMPLEX AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012054716-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV. (BE) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012054716-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV. (BE) | 2012-04-26 | — | — | WO | disclosed |
| US-20110207702-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | disclosed |
| US-7834194-B2 | Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2010045503-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| EP-1830840-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070921-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | XBP1, HSPA5, DNAJC10 | BCKDK 2354/4885RAB9A 1084/4885SENP1 1384/4885 |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | BCKDK 742/4885RAB9A 851/4885SENP1 2774/4885 |
| US-20110207702-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | BRDT, BRI3BP, BTN3A1 | BCKDK 2792/4885RAB9A 196/4885SENP1 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.